Senolytics: The Honest Protocol Is Mostly Restraint
Trial protocols use intermittent doses roughly ten times consumer labels, there is no way to measure whether anything was cleared, and daily low-dose use is a different intervention entirely.
The Short Answer
Senolytics have the strongest mechanistic case of any direction in ageing biology and the weakest case for consumer use, which is an awkward combination the market has resolved by ignoring the second half. Trial protocols use intermittent high doses roughly an order of magnitude above consumer labels. No validated assay measures senescent cell burden, so an individual cannot know whether anything worked. And the daily low-dose products on sale are not a milder version of the studied protocol, they are a different intervention with no evidence base.
Why the Mechanism Is Genuinely Interesting
Senescent cells stop dividing but resist death, and they secrete a pro-inflammatory profile that damages surrounding tissue and can induce senescence in neighbouring cells. Clearance declines with age, so burden accumulates.
The animal evidence is unusually strong. Genetic clearance of senescent cells in mice delayed cataracts, sarcopenia and adipose loss, improved cardiac and kidney function, and extended median lifespan substantially in one prominent study. Pharmacological clearance improved cardiovascular and physical function in aged mice with benefits persisting beyond the dosing period. Injecting a relatively small number of senescent cells into young mice produced measurable functional loss, which is close to a demonstration of causation.
The intermittent dosing finding is the design-relevant one. Because benefits outlast the drug, senolytics are conceived as periodic clearance rather than daily compounds, which is the opposite of how every consumer product is sold.
The Cluster 2 article covers the biology and the human trial stage in more depth.
The Dose Gap, Quantified
| Trial protocol | Consumer product | |
|---|---|---|
| Fisetin dose | Around 20 mg per kg body weight | Typically 100 to 500 mg total |
| For an 80 kg adult | Roughly 1.6 g per day during a pulse | 100 to 500 mg |
| Schedule | Two or three consecutive days, repeated monthly | Daily, indefinitely |
| Dasatinib plus quercetin | Prescription cancer medicine with high-dose quercetin, intermittent | Quercetin alone, daily, low dose |
| Endpoint measured | Senescent cell markers in biopsied tissue | Nothing measurable |
The gap is roughly an order of magnitude in dose and inverted in schedule. That combination means consumer fisetin use is not an attenuated version of the studied intervention.
Fisetin's poor oral bioavailability widens the gap further, since a fraction of an already smaller dose reaches circulation. Formulation matters and is rarely specified.
The last row is the one that makes individual use unmeasurable. Trials assess senescent cell markers in biopsied adipose tissue or skin. There is no blood test, no imaging measure and no consumer assay, so a person taking fisetin has no way to know whether any clearance occurred.
The Human Trial Stage, Accurately
Human work is small, mostly open-label and early.
A pilot study in idiopathic pulmonary fibrosis using dasatinib plus quercetin reported improved physical function in 14 patients without a control group. A small open-label study in diabetic kidney disease reported reduced senescent cell burden in adipose tissue and skin after a short intermittent course. Trials in osteoarthritis, Alzheimer's disease, frailty and bone loss are underway or reported at small scale, with mixed early results including at least one negative osteoarthritis trial of a locally injected agent.
What does not exist: any randomised controlled trial showing improved clinical outcomes in humans, any long-term safety data, any validated biomarker of burden usable in practice, and any established dosing schedule for healthy people.
That is a reasonable place for a field to be nine years into serious pharmacological work. It is not a reasonable basis for a consumer protocol.
The Safety Questions That Matter
Senescence is protective as well as harmful. It suppresses tumour formation by stopping damaged cells dividing, so broad clearance could in principle remove a tumour-suppressing mechanism. A mouse study running two years cannot detect a cancer risk that would emerge over human decades.
Wound healing. Senescent cells participate in it, and clearing them impairs healing in animal models. Relevant around surgery or injury.
Heterogeneity. Senescent populations differ by tissue with different survival dependencies, so no single compound clears all of them and none clears only the harmful ones.
Quercetin's interaction profile. Substantial CYP3A4 and P-glycoprotein effects, which matter for anyone on common medications and are rarely mentioned on labels. At the high doses trial protocols use, this is not a minor consideration.
Dasatinib. A prescription tyrosine kinase inhibitor with a substantial side-effect profile including cytopenias, fluid retention and pleural effusion. Obtaining it outside clinical care for this purpose is a serious risk.
Unknown long-term effects. No human has taken intermittent senolytics for decades, so the honest answer about long-term safety is that nobody knows.
The Protocol That Is Defensible
Since the compounds cannot be recommended, the protocol is the set of things that reduce senescent burden with evidence behind them.
Exercise. Reduces senescence markers in human tissue, which is the only senolytic-adjacent intervention with human evidence and no risk. Both aerobic and resistance training.
Avoid the inducers. Senescence is triggered by DNA damage, oxidative stress, telomere attrition and metabolic stress. Practically that means not smoking, ultraviolet protection, glycaemic control and reducing sustained inflammatory load.
Reduce visceral adiposity, since adipose tissue hosts senescent cells and inflammatory macrophage populations.
Sleep and inflammatory load, both of which feed the same process.
Watch the field. Following costs nothing. Within a decade there may be a validated burden assay and a licensed agent with outcome data, at which point this becomes a genuinely different conversation.
That is the whole defensible protocol, and it consists entirely of things worth doing anyway. The parts specific to senolytics are the parts that cannot be verified.
If Someone Proceeds Anyway
People will, so harm reduction is worth stating plainly rather than withheld.
Understand what you are running. An uncontrolled experiment with an unmeasurable endpoint, at a dose that either matches a trial protocol and carries its unknowns, or falls far below it and matches nothing studied.
Intermittent rather than daily, if following the research logic at all. Daily low-dose use is the design the animal work argues against.
Check every medication against quercetin's CYP3A4 and P-glycoprotein effects, which is not optional at high doses.
Not around surgery or injury, given the wound healing consideration.
Not with a personal or family history of cancer without clinical input, given the tumour suppression mechanism.
Not obtained as dasatinib outside clinical care. That is a prescription oncology drug with a serious profile.
Tell your clinician, which people frequently do not.
Set an endpoint. Without a measurable outcome, the only alternative to indefinite use is a predetermined stop date.
None of this makes it advisable. It makes the difference between a poorly informed version and a slightly less poorly informed one.
The AEONNN Perspective
AEONNN places senolytics at Evidence Level C and the reason is measurement rather than general caution. Without a validated assay for senescent cell burden there is no way to personalise the intervention or to observe whether it did anything, and a platform built on measurement cannot recommend an unmeasurable one.
The Pharmacokinetics layer carries the single most useful fact for a member: trial fisetin protocols use around 20 mg per kilogram intermittently, roughly 1.6 g daily during a pulse for an 80 kg adult, against consumer capsules of 100 to 500 mg labelled for daily use. That is an order of magnitude in dose and an inversion in schedule, so the daily product is a different intervention rather than a milder one.
The Safety layer holds three things labels omit: senescence suppresses tumour formation, so broad clearance carries a theoretical risk no rodent study can resolve; senescent cells participate in wound healing; and quercetin's CYP3A4 and P-glycoprotein effects are substantial at trial doses. What the platform does recommend is the part with human evidence, which is exercise, since it reduces senescence markers in human tissue at no risk.
Pillar Matrix mapping
Longevity and Biological Age, Inflammation and Immune Defense
Database Matrix layers
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Pharmacokinetics Layer (HMDB, PubChem)
- Safety Layer (DrugBank, FAERS)
- Innovation Layer (bioRxiv preprints, patent filings)
Frequently Asked
What dose do senolytic trials use?
Fisetin protocols commonly use around 20 mg per kilogram body weight for two or three consecutive days, repeated monthly. For an 80 kg adult that is roughly 1.6 g daily during the pulse.
Is daily low-dose fisetin the same thing?
No. It is roughly an order of magnitude below the trial dose and inverted in schedule, since the animal work argues for intermittent clearance because benefits outlast the dosing.
Can I measure whether senolytics worked?
No. Trials assess senescent cell markers in biopsied tissue. There is no blood test, imaging measure or consumer assay, which makes individual use unmeasurable.
What are the safety concerns?
Senescence suppresses tumour formation, so broad clearance carries a theoretical cancer risk short animal studies cannot rule out. Senescent cells also participate in wound healing, and quercetin has substantial drug interactions.
Has any human trial shown clinical benefit?
No randomised controlled trial has shown improved clinical outcomes. Human work is small, mostly open-label, and includes at least one negative osteoarthritis trial.
What reduces senescent cells with actual evidence?
Exercise reduces senescence markers in human tissue. Avoiding the inducers, smoking, ultraviolet damage, chronic hyperglycaemia and sustained inflammatory load, reduces accumulation.
When would this change?
If a validated burden assay and a licensed agent with outcome data arrive, which is plausible within a decade. Following the field costs nothing.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.